ATE465266T1 - Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren - Google Patents

Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren

Info

Publication number
ATE465266T1
ATE465266T1 AT99966715T AT99966715T ATE465266T1 AT E465266 T1 ATE465266 T1 AT E465266T1 AT 99966715 T AT99966715 T AT 99966715T AT 99966715 T AT99966715 T AT 99966715T AT E465266 T1 ATE465266 T1 AT E465266T1
Authority
AT
Austria
Prior art keywords
alphavirus
vectors
packaging
nucleic acid
methods
Prior art date
Application number
AT99966715T
Other languages
English (en)
Inventor
John Polo
Barbara Belli
Thomas Dubensky
Stephen Hardy
Perri Silvia
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE465266T1 publication Critical patent/ATE465266T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151Methods of production or purification of viral material
    • C12N2770/36152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Laminated Bodies (AREA)
  • Packages (AREA)
  • Wrappers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT99966715T 1998-12-31 1999-12-30 Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren ATE465266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11473298P 1998-12-31 1998-12-31
PCT/US1999/031193 WO2000039318A1 (en) 1998-12-31 1999-12-30 Compositions and methods for packaging of alphavirus vectors

Publications (1)

Publication Number Publication Date
ATE465266T1 true ATE465266T1 (de) 2010-05-15

Family

ID=22357098

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99966715T ATE465266T1 (de) 1998-12-31 1999-12-30 Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren

Country Status (7)

Country Link
US (1) US6242259B1 (de)
EP (1) EP1141361B1 (de)
AT (1) ATE465266T1 (de)
AU (1) AU2220800A (de)
CA (1) CA2359013C (de)
DE (1) DE69942280D1 (de)
WO (1) WO2000039318A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
US6423544B1 (en) * 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
EP1035205A1 (de) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Sich nicht verbreitendes Pestivirus
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
WO2002062949A2 (en) * 2000-10-20 2002-08-15 Canji, Inc Aptamer-mediated regulation of gene expression
CN1520303B (zh) * 2001-03-27 2013-04-24 纽约大学 利用基于α病毒且靶向高亲和性层粘连蛋白受体的载体进行肿瘤治疗
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
WO2003029492A1 (en) * 2001-09-28 2003-04-10 Justin Gallivan Metabolic genes and related methods and compositions
US20050215472A1 (en) * 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2003034903A2 (en) * 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
WO2004033653A2 (en) * 2002-10-10 2004-04-22 Oxford Biomedica (Uk) Limited Gene regulation with aptamer and modulator complexes for gene therapy
US20040208848A1 (en) 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
NZ540657A (en) * 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
CN1791678A (zh) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
EP1751289B1 (de) 2004-05-18 2009-01-14 Alphavax, Inc. Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren
US20090104226A1 (en) 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
CA2572921C (en) * 2004-07-09 2017-01-03 The University Of North Carolina At Chapel Hill Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
CA2597921A1 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
EP2567976B1 (de) 2005-03-23 2017-07-19 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
CA2626253A1 (en) 2005-10-18 2007-04-26 Novartis Vaccines And Diagnostics, Inc. Mucosal and systemic immunizations with alphavirus replicon particles
NZ575901A (en) 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
NZ576563A (en) * 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
AU2008319053B2 (en) 2007-11-01 2012-04-26 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
ES2525707T3 (es) 2008-12-01 2014-12-29 Alphavax, Inc. Uso de microRNAs para el control de ácidos nucleicos colaboradores de virus
US20120128714A1 (en) 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
US20140093556A1 (en) 2011-01-28 2014-04-03 Sanofi Pasteur Sa Immunological Compositions Against HIV
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
JP2019511255A (ja) 2016-01-11 2019-04-25 バーンダリ,インク. マイクロニードル組成物およびそれを使用する方法
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
DE69738521T2 (de) 1996-04-05 2009-05-07 Novartis Vaccines and Diagnostics, Inc., Emeryville Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen

Also Published As

Publication number Publication date
EP1141361B1 (de) 2010-04-21
US6242259B1 (en) 2001-06-05
CA2359013A1 (en) 2000-07-06
CA2359013C (en) 2011-02-01
WO2000039318A1 (en) 2000-07-06
DE69942280D1 (de) 2010-06-02
AU2220800A (en) 2000-07-31
EP1141361A1 (de) 2001-10-10

Similar Documents

Publication Publication Date Title
ATE465266T1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
DE60042969D1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
DE69834908D1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
ZA967173B (en) Purified coprinus laccases and nucleic acids and encoding same
DE69738521D1 (de) Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
CA2400295A1 (en) Modified factor viii
ATE312176T1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
WO1999011764A3 (en) Methods for generating high titer helper-free preparations of recombinant aav vectors
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
DK0804558T3 (da) Tripeptidylaminopeptidase
ATE454039T1 (de) Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung
DE69504808D1 (de) Corticotropin freisetzende rezeptoren des faktor 2
DK1082423T3 (da) Cyclin E2-gener og -proteiner
DE60117998D1 (de) Mutierte furin polypeptide, welche verbesserte eigenschaften aufweisen
DE69619808D1 (de) Chimäre msp und daf proteine mit einem telloberflächenlokalisierendem domän
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
DE60026049D1 (de) POLYPEPTIDE MIT GLUCANOTRANSFERASE AKTIVITÄT UND DAFüR KODIERENDE NUKLEINSÄUREN
BR9611851A (pt) Molécula de ácido nucléico isolada e purificada, vetor de experessão recombinatória, célula hospedeira contendo um vetor de expressão recombina tório, proteìnas tbpa e tbpb isolada e purificadas, método para preparar uma protéina tbpa e tbpb, anti-corpo policlÈnico ou monoclÈnico, e vacinas assim obtidas
ATE268820T1 (de) Herstellung von heterloge proteine
ATE318920T1 (de) Promotoren zur genexpression in karyopsen von pflanzen
DK0870050T3 (da) Virus, der udtrykker et toksisk protein, og producercellelinier
DK1277833T3 (da) Gener, der opformeres i tumorer, samt relaterede materialer og metoder
WO2000026340A3 (en) Novel nucleic acid molecules encoding opioid growth factor receptors
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141361

Country of ref document: EP